Uncoupling of rat and human mitochondria: A possible explanation for tacrine-induced liver dysfunction

被引:55
作者
Berson, A
Renault, S
Letteron, P
Robin, MA
Fromenty, B
Fau, D
LeBot, MA
Riche, C
DurandSchneider, AM
Feldmann, G
Pessayre, D
机构
[1] HOP BEAUJON,ASSOC CLAUDE BERNARD,CTR RECH PHYSIOPATHOL HEPAT,F-92118 CLICHY,FRANCE
[2] HOP MORVAN,SERV PHARMACOL,BREST,FRANCE
[3] FAC XAVIER BICHAT,INSERM U327,PARIS,FRANCE
关键词
D O I
10.1053/gast.1996.v110.pm8964414
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Tacrine administration (1-3 mg/kg) may lead to sinusoidal concentrations in the micromolar range and produce liver dysfunction in 50% of recipients, The aim of this study was to determine the cellular effects of tacrine that account for liver dysfunction, Methods: The effects of tacrine on mitochondrial function were determined in isolated rat liver mitochondria, cultured rat hepatocytes, and isolated human lymphocytes, Results: In vitro, tacrine was taken up by rat liver mitochondria, decreased their membrane potential, and stimulated their respiration, Ex vivo, respiration was increased in rat mitochondria isolated 30 minutes after the administration of 2 mg of tacrine per kilogram, After 7 days of culture, tacrine (2.5 mu mol/L) decreased rat hepatocyte adenosine triphosphate levels, Ten micromolar decreased 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium reduction and neutral red uptake without modifying cell glutathione, the morphology of the endoplasmic reticulum, or protein synthesis, Tacrine (1.25 mu mol/L) decreased levels of adenosine triphosphate in human lymphocytes. Conclusions: The weak base tacrine exerts a protonophoric effect in mitochondria that wastes energy and decreases levels of adenosine triphosphate in rat and human cells. These effects are visible after clinically relevant doses of tacrine and might be involved in tacrine-induced fiver dysfunction.
引用
收藏
页码:1878 / 1890
页数:13
相关论文
共 39 条
  • [1] BECQUEMONT L, IN PRESS FUND CLIN P
  • [2] BERSON A, 1994, J PHARMACOL EXP THER, V270, P167
  • [3] Borenfreund E., 1984, J. Tissue Cult. Methods, V9, P7, DOI DOI 10.1007/BF01666038
  • [4] FLUVOXAMINE IS A POTENT INHIBITOR OF CYTOCHROME-P4501A2
    BROSEN, K
    SKJELBO, E
    RASMUSSEN, BB
    POULSEN, HE
    LOFT, S
    [J]. BIOCHEMICAL PHARMACOLOGY, 1993, 45 (06) : 1211 - 1214
  • [5] A DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF TACRINE FOR ALZHEIMERS-DISEASE
    DAVIS, KL
    THAL, LJ
    GAMZU, ER
    DAVIS, CS
    WOOLSON, RF
    GRACON, SI
    DRACHMAN, DA
    SCHNEIDER, LS
    WHITEHOUSE, PJ
    HOOVER, TM
    MORRIS, JC
    KAWAS, CH
    KNOPMAN, DS
    EARL, NL
    KUMAR, V
    DOODY, RS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (18) : 1253 - 1259
  • [6] TACRINE
    DAVIS, KL
    POWCHIK, P
    [J]. LANCET, 1995, 345 (8950) : 625 - 630
  • [7] ANTICHOLINESTERASIC DRUGS - TACRINE BUT NOT PHYSOSTIGMINE, ACCUMULATES IN ACIDIC COMPARTMENTS OF THE CELLS
    DELLATONE, P
    BRAGADIN, M
    ZATTA, P
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1995, 1270 (2-3): : 137 - 141
  • [8] DESCHAMPS D, 1994, HEPATOLOGY, V19, P948, DOI 10.1002/hep.1840190422
  • [9] FARRIS MW, 1994, HEPATOLOGY, V20, P20
  • [10] FAU D, 1992, J PHARMACOL EXP THER, V263, P69